In phase III trials, both agents were shown to prolong progression free survival in patients with metastatic RCC and temsirolimus prolonged overall survival, validating the mTOR pathway as an important target for the treatment of RCC [8], [10]. Here, MTOR is linked to renal cell carcinoma.